Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/49886
Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
S100A4, a member of the S100 calcium-binding protein family secreted by tumor and stromal cells, supports tumorigenesis by stimulating angiogenesis. We demonstrated that S100A4 synergizes with vascular endothelial growth factor (VEGF), via the RAGE receptor, in promoting endothelial cell migration by increasing KDR expression and MMP-9 activity. In vivo overexpression of S100A4 led to a significant increase in tumor growth and vascularization in a human melanoma xenograft M21 model. Conversely, when silencing S100A4 by shRNA technology, a dramatic decrease in tumor development of the pancreatic MiaPACA-2 cell line was observed. Based on these results we developed 5C3, a neutralizing monoclonal antibody against S100A4. This antibody abolished endothelial cell migration, tumor growth and angiogenesis in immunodeficient mouse xenograft models of MiaPACA-2 and M21-S100A4 cells. It is concluded that extracellular S100A4 inhibition is an attractive approach for the treatment of human cancer.
Matèries (anglès)
Citació
Citació
HERNÁNDEZ, José luis, PADILLA GARCÍA, Laura, DAKHEL, Sheila, COLL, Toni, HERVAS, Rosa, ADAN, Jaume, MASA, Marc, MITJANS, Francesc, MARTÍNEZ CRESPO, Josep m. (josep maria), COMA I BASSAS, Sílvia, RODRÍGUEZ GALLEGO, Laura, NOÉ MATA, Verónica, CIUDAD I GÓMEZ, Carlos julián, BLASCO, Francesc, MESSEGUER I PEYPOCH, Ramon. Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. _PLoS One_. 2013. Vol. 8, núm. 9, pàgs. e72480. [consulta: 23 de gener de 2026]. ISSN: 1932-6203. [Disponible a: https://hdl.handle.net/2445/49886]